Glycan News and Research

RSS

ProtAffin signs manufacturing contract with CMC Biologics for COPD drug PA401

ProtAffin AG, a biotechnology company developing a novel class of biopharmaceutical products that act by targeting cell-surface glycan structures, today announced it has signed a manufacturing contract with CMC Biologics' Danish operations, located in Copenhagen, Denmark for manufacture of its lead product PA401 for the treatment of chronic obstructive pulmonary disease (COPD). The contract will cover manufacture and supply of PA401 for preclinical development and early clinical development in COPD and related respiratory indications.

27 Jul 2010

Scientists discover gene mutation responsible for CDG

An international team of scientists, led by researchers at the University of California, San Diego School of Medicine, has discovered the gene mutation responsible for a condition in which eye and brain development is severely disrupted in affected infants.

16 Jul 2010

UC researchers receive $2.3M grant to develop user-friendly diagnostics for influenza virus

Researchers at the University of Cincinnati have received a five-year grant to develop rapid, robust, user-friendly diagnostics for influenza virus. An interdisciplinary team of scientists has received a $2.3 million dollar grant from the National Institute for Allergy and Infectious Diseases, one of the National Institutes of Health. The name of the grant is "Glycan Receptor Mimics for Rapid Detection, Typing, and Susceptibility Testing of Influenza."

17 Jun 2010

Research findings open door to development of new therapies for lymphomas, leukemias

Scripps Research Institute scientists have discovered a new way to target and destroy a type of cancerous cell. The findings may lead to the development of new therapies to treat lymphomas, leukemias, and related cancers.

8 Jun 2010

Early detection and removal of pancreatic cysts may lower cancer risk: Researchers

Working with researchers from the University of Michigan and Indiana University, Van Andel Research Institute investigators have developed a method that could be used to predict whether pancreatic cysts are benign or are precursors to invasive cancer.

4 Jun 2010

New HPLC-Chip introduced to address N-glycan analysis in biopharmaceutical market

Agilent Technologies Inc. today introduced a new HPLC-Chip to address N-glycan analysis in the emerging biopharmaceutical market.

25 May 2010

Promosome signs technology license and partnership agreement with Recopharma AB of Stockholm

Promosome LLC, a biotechnology company uniquely dedicated to the development of technologies related to the regulation of protein synthesis through translation initiation, today announced the signing of a technology license and partnership agreement with Recopharma AB of Stockholm, Sweden. Recopharma is a recognized leader in the research and development of therapeutic recombinant mucin-type fusion proteins.

19 May 2010

BSD, ProZyme partner to redefine biotherapeutic glycan analysis workflow

BioSystem Development, LLC (BSD) and ProZyme, Inc. announce a partnership to redefine biotherapeutic glycan analysis workflow. The first product from this collaboration combines ProZyme's proprietary enzymatic N-deglycosylation, labeling and cleanup chemistry with BSD's AssayMAP™ high- throughput micro chromatography platform resulting in a rapid, quantitative N-glycan sample preparation method fully enabled for any scale of automation.

11 May 2010

New understanding of CD44 receptor's role in immune cell survival

Investigators at Sanford-Burnham Medical Research Institute (Sanford-Burnham) have discovered a new way the cell surface protein, CD44, helps specific T helper (Th1) cells develop immunologic memory.

29 Jan 2010

Copper-free version of click chemistry crafted to create biomolecular probes

For the first time, the widely used molecular synthesis technique known as click chemistry has been safely applied to a living organism. Researchers with Lawrence Berkeley National Laboratory (Berkeley Lab) and the University of California (UC) Berkeley have crafted a unique copper-free version of click chemistry to create biomolecular probes for in vivo studies of live mice. Conventional click chemistry reactions require a copper catalyst that is toxic to cells and organisms.

20 Jan 2010

Researchers develop new technique to study the mechanisms behind diseases in more detail

Researchers have previously been able to analyse which sugar structures are to be found on certain proteins, but not exactly where on the protein they are positioned. This is now possible thanks to a new technique developed at the Sahlgrenska Academy at the University of Gothenburg, Sweden.

20 Oct 2009

HIV mutates itself to escape antibodies

A study of how HIV mutates in response to immune system pressure by Emory Vaccine Center researchers shows that the virus can take several escape routes, not one preferred route.

21 Sep 2009

Anti-glycan antibody positivity observed in celiac disease

Anti-microbial antibody formation has been reported in celiac disease. Relatively high positivity rates were observed for the conventional antibodies, for example, ASCA, anti-OmpW, and anti-I2, and they were known to decrease after a successful gluten free-diet. The importance of newly discovered inflammatory bowel disease-associated antibodies (including anti-glycan antibodies and anti-OMP) in celiac disease is not sure.

26 Aug 2009

Specialized glycans act as tumor suppressors

Scientists at Burnham Institute for Medical Research (Burnham) have discovered that specialized complex sugar molecules (glycans) that anchor cells into place act as tumor suppressors in breast and prostate cancers.

6 Jul 2009

New therapy improves chances of living disease-free with neuroblastoma

A phase III study has shown that adding an antibody-based therapy that harnesses the body's immune system resulted in a 20 percent increase in the number of children living disease-free for at least two years with neuroblastoma.

15 May 2009

Carbohydrate-based medicine

Scientists from Germany today reported a major advance toward opening the doors of a carbohydrate-based medicine chest for the 21st Century.

22 Mar 2009

First-ever glimpse of the cell-wall structure in three dimensions

The bacterial cell wall that is the target of potent antibiotics such as penicillin is actually made up of a thin single layer of carbohydrate chains, linked together by peptides, which wrap around the bacterium like a belt around a person, according to research conducted by scientists at the California Institute of Technology (Caltech).

17 Nov 2008

Systems biology and glycomics used to study human inflammatory diseases

An innovative systems biology approach to understanding the carbohydrate structures in cells is leading to new ways to understand how inflammatory illnesses and cardiovascular disease develop in humans. The work was described in two recent publications by University at Buffalo chemical engineers.

28 Oct 2008

Ashwell receptor plays key role in reducing coagulation abnormalities during infection and sepsis

In research that solves the longest-standing mystery in glycobiology - a field that studies complex sugar chains called glycans - researchers at the University of California, San Diego School of Medicine have discovered that a molecule in the liver of all animals, called the Ashwell receptor, is critical in helping the body fight off the abnormal and lethal blood clotting caused by bacterial infection.

19 May 2008

New sugary insights into H5N1 avian flu virus

Scientists have identified a key factor that determines the ability of influenza viruses to infect cells of the human upper respiratory tract - a necessary step for sustaining spread between people.

7 Jan 2008